Probenecid Administration for Alcohol Craving and Consumption
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBrown University
About this trial
This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.
Eligibility criteria
Qualifiers
• Male or female, ≥18 years.
women >7 drinks/week; men >14 drinks/week.
meet moderate to severe AUD score for DSM-5 criteria.
Breath Alcohol Content (BrAC)=0.00 at each visit.
Disqualifiers
• Women who are breastfeeding or positive urine test for pregnancy.
clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin >150% of the upper normal limit, ALT/AST >300% the UNL, creatinine clearance ≤60 dl/min
meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses
medications that reduce alcohol consumption (naltrexone, disulfiram).
Trial design
Treatments tested in this trial
- Probenecid Oral Tablet
- Placebo Oral Tablet
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov